Bisphosphonate Treatment of Osteogenesis Imperfecta

Bisphosphonate Therapy for Osteogenesis Imperfecta (OI)

Bisphosphonates are a standard first-line treatment for individuals with moderate to severe Osteogenesis Imperfecta (OI), also known as brittle bone disease. These medications help to:

- Increase bone mineral density
- Reduce bone pain
- Lower fracture risk
- Improve mobility and quality of life

They work by slowing bone resorption (breakdown) and supporting a healthier balance between bone formation and breakdown. While individual responses can vary, two commonly used intravenous bisphosphonates in OI treatment are:

- Pamidronate
- Zoledronic acid

What Are Bisphosphonates?

Bisphosphonates are a group of medications designed to prevent bone loss by targeting osteoclasts—the cells responsible for breaking down bone. By inhibiting bone resorption, these drugs help strengthen bones and reduce the risk of fractures.

How They Work

- Bisphosphonates were developed in the 1970s for adult conditions like osteoporosis and Paget's disease.
- Their chemical structure mimics pyrophosphate, a natural substance in the body that prevents unwanted calcium deposits.

- This structure allows bisphosphonates to bind to calcium crystals in bone, where they act directly on osteoclasts.

Common Uses of Bisphosphonates

These medications are used to treat a range of bone-related conditions, including:

- Osteogenesis Imperfecta (OI)
- Osteoporosis
- Paget's disease of bone
- Multiple myeloma
- Bone complications related to cancer

Administration Methods

Bisphosphonates can be given in two main ways:

- Orally (tablets)
  e.g., Alendronate (Fosamax), Risedronate (Actonel)
- Intravenously (IV infusion)
  e.g., Pamidronate, Zoledronic acid (Zometa)

How Do Bisphosphonates Work?

Bone health depends on a dynamic process known as **bone turnover**, involving two key types of bone cells:

- **Osteoblasts**: Build new bone.
- **Osteoclasts**: Break down old bone (bone resorption).

In healthy individuals, bone resorption and bone formation are balanced. However, in people with **Osteogenesis Imperfecta (OI)**, this balance is disrupted—more bone is broken down than replaced.

Bisphosphonates work by **inhibiting osteoclast activity**, thereby reducing bone resorption. Since osteoblasts continue to form new bone, the treatment shifts the balance toward increased bone mass and density.

Research and Clinical Use

Since the mid-1990s, research in children with OI has shown that bisphosphonates offer several benefits:

- Increased bone density
- Decreased bone pain
- In some cases, reduced fracture rates

Modes of Administration

- **Intravenous (IV)**: Commonly used drugs include **Pamidronate**, **Zoledronic Acid**, and **Etidronate**.
- **Oral**: Includes **Risedronate** and **Alendronate**.

Initial studies primarily involved children with moderate to severe OI. More recent research includes mildly affected children, with promising results using oral bisphosphonates.

Potential Side Effects

Short-Term Reactions (IV Bisphosphonates)

- Flu-like symptoms (fever, aches, fatigue) after first dose
- Symptoms typically resolve within 2–3 days and do not usually recur with subsequent treatments

Bone Healing

- **Delayed healing** after surgical procedures like **osteotomy** (surgical cutting of bone to insert rods)
- Treatment is often paused before surgery and resumed only after confirmed bone healing

Note: There is no evidence that bisphosphonates delay healing after fractures or impair a child's normal growth.

Gastrointestinal Issues (Oral Bisphosphonates)

- Stomach discomfort
- Irritation of the oesophagus if not taken as instructed

Osteonecrosis of the Jaw (ONJ)

- Rare side effect mostly reported in **adults with cancer** on high-dose IV bisphosphonates
- **No reports in children with OI**

- **Dental hygiene is critical**—regular dental checkups are recommended, and dental professionals should be informed of bisphosphonate use before any procedure, especially extractions

Specific dental procedures (e.g., orthodontic treatment, implants) may require specialist input for patients on bisphosphonates.

Limitations and Considerations

Bisphosphonates **do not correct the underlying collagen defect** in OI. They are not a cure but can significantly improve bone density and reduce fractures in many cases. Treatment should be supervised by a **multidisciplinary team**, including:

- Orthopaedic surgeons
- Physiotherapists
- Occupational therapists

Frequently Asked Questions

Can Bisphosphonates Improve Other OI Symptoms?

No. While they help with bone fragility, bisphosphonates **do not improve**:

- Joint laxity
- Muscle weakness
- Short stature

Some studies suggest early bisphosphonate use may delay or prevent **scoliosis**.

How Long is Treatment Needed?

The duration varies. Bone density improvements may reverse if treatment is stopped, and **density does not always equal strength**. Pain relief is another benefit that may persist even after stopping treatment.

What About Physical Therapy and Nutrition?

Bisphosphonates are most effective when combined with:

- **Calcium and Vitamin D** supplementation
- **Individualised exercise programs** designed by professionals

Physical therapy is always beneficial for individuals with OI.

What Do We Still Not Know?

Despite over a decade of use in children with OI, many questions remain:

- Are there **long-term side effects**?
- Does increased density = improved **bone strength**?
- How do bisphosphonates affect different bones (e.g., spine vs. limbs)?
- What's the best **dose and delivery method** for different OI types and age groups?
- Should children with **mild OI** receive treatment?

Adult and paediatric responses differ. Children show quicker density changes but may have more side effects with IV treatments.

Research Highlights

Key Studies

- **POISE Study (Risedronate)**:
    - 50% reduction in fracture risk
    - Increased bone density
    - Benefits seen **before** significant density increase, suggesting reduced osteoclast activity may play a role
- **Shriners Hospital Study (Alendronate)**:
    - Less benefit in more severely affected children
    - Implies **more severe OI** may require **IV therapy or higher doses**
- **UK Dose Study (Risedronate)**:
    - Higher doses yielded better density gains
    - Study too small to assess fracture rates

When to Start Treatment?

No standardised criteria currently exist. Generally accepted indications include:

- Multiple vertebral fractures
- Fractures impairing mobility or requiring repeated surgery
- Persistent bone pain

Decisions for **mildly affected individuals** should be made on a case-by-case basis, in consultation with a specialist team.

Looking Ahead

While bisphosphonates have significantly improved the quality of life for many with OI, they are not perfect. A **50% reduction in fractures** is impressive, but a treatment that **eliminates fractures** remains the ultimate goal. New treatments are under investigation.

Until those studies are complete, bisphosphonates remain the most effective option—**but more research is needed**.

Final Note

Because bisphosphonate treatment for OI is still considered **investigational**, participation in clinical trials is encouraged. This ensures expert supervision and helps contribute to the growing body of knowledge that benefits the entire OI community.

References

Botor, M., Fus-Kujawa, A., Uroczynska, M., Stepien, K. L., Galicka, A., Gawron, K., & Sieron, A. L. (2021). Osteogenesis Imperfecta: Current and Prospective Therapies. *Biomolecules*, *11*(10), 1493. https://doi.org/10.3390/biom11101493

Drake, M. T., Clarke, B. L., & Khosla, S. (2008). Bisphosphonates: mechanism of action and role in clinical practice. *Mayo Clinic proceedings*, *83*(9), 1032–1045. https://doi.org/10.4065/83.9.1032

Dwan, K., Phillipi, C. A., Steiner, R. D., & Basel, D. (2016). Bisphosphonate therapy for osteogenesis imperfecta. *The Cochrane database of systematic reviews*, *10*(10), CD005088. https://doi.org/10.1002/14651858.CD005088.pub4